Abstract
One of the major precepts in the practice of modern medicine is to quantify endogenous constituents in biological fluids as an aid to diagnosis of disease and to monitor therapy. Measurement of endogenous biochemicals comprises clinical chemistry. Clinical chemistry tests are extremely valuable to the clinician; in fact major industries have developed to support them. In the development of many new drugs, the drug development process has also taken advantage of standard clinical chemistry tests to provide an early assessment about the potentially toxic and/or efficacious potential of drug candidates. The availability of these tests can streamline the drug discovery and development process by making decisive high quality data available at a time point well before a definitive morphologic response is evident. However, in the development of a novel drug, the clinical chemistry tests to address a target efficacy or toxicity are not always available, and this lack of an early indicator greatly increases the risk and expense of going forward with drug development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Annan R. Proteolytics and Biological Mass Spectrometry. Land O’Lakes Bioanalytical Conference, Devil’s Head, WI (2000).
Antti H, Brindle J, Shockcor J et al. Multivariate statistical pre-treatment of NMR-based metabonomics data to remove inherent physiological variation confounding toxicit patterns. 41st Meeting of the Society of Toxicology, Nashville (2002).
Bales JR, Higham DP, Howe I et al. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi component analysis of urine. Clin Chem 30: 426–432 (1984).
Beckwith-Hall BM, Nicholson JK, Nicholls AW et al. Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem Res Toxicol 11: 260–272 (1998).
Beckwith-Hall BM, Holmes E, Lindon JC et al. NMR-based metabonomic studies on the biochemical effects of commonly used drug carrier vehicles in the rat. Chem Res Toxicol in press (2002).
 Bell JD, Sadler PJ, Morris VC, Levander OA. Effect of aging and diet on proton NMR spectra of rat urine. Magn Reson Med 17: 414–422 (1991).
Bollard ME, Holmes E, Lindon JC et al. Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution 1H NMR spectroscopy of urine and pattern recognition. Anal Biochem 295: 194–202 (2001).
Espina JR, Shockcor JP, Herron WJ et al Detection of in vivo biomarkers of phospholipodosis using NMR-based metabonomics approaches. Magn Reson Chem 28: 559–565(2001).
Foxall PJD, Bending M, Gartland KPR, Nicholson JK. Acute renal failure following accidental cutaenous exposure to phenol: application of PMR urinalysis to monitor the disease process. Human Toxicol 9: 441–449 (1989).
Foxall PJD, Mellotte GJ, Bending MR et al NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Intl 43: 234–245 (1993).
Gartland KPR, Lindon JC, Beddell J, Nicholson JK. Application of pattern recognition methods to the analysis of toxicological data generated by NMR spectroscopy. Mol Pharmacol 39: 629–642 (1991).
Gavaghan CL, Nicholson JK, Connor SC et al. HPLC-NMR spectroscopic and chemometric studies on metabolic variation in Sprague-Dawley rats. Anal Biochem 291: 245–252 (2001).
Gygi SP, Rochon Y, Franza BR et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720–1730 (1999).
Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnol 17: 994–999 (1999).
Holland JF, Leary JJ, Sweeley CC. Advanced instrumentation and strategies for metabolic profiling J Chromator Biomed Appl 379: 3–26 (1986).
Holmes E, Foxall PJD, Neild GH et al. Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal Biochem 220: 284–296 (1994).
Holmes E, Nicholls AW, Lindon JC et al. Development of a model for classification of toxin-induced lesions using 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed 11: 235–44 (1998).
Holmes E, Nicholls AW, Lindon JC et al. Chemometric models for toxicity classification based on NMR spectra of biofluids. Chem Res Tox 13: 471–478 (2000).
Holmes E. Application of Metabonomics Expert Systems to the Study of Physiological and Toxicological Variation. 41st Meeting of the Society of Toxicology, Nashville (2002).
Kennedy T. Managing the drug discovery /development interface. Drug Discov Today 2: 436–444 (1997).
Lindon JC, Nicholoson JK, Holmes E et al. Metabonomics in toxicology: the COMET project. Toxicol Appl Pharmacol submitted (2002).
Nicholls AW, Nicholson JK, Haselden JN, Waterfield CJ. A metabonomic approach to the investigation of drug induced phospholipodosis. Biomarkers 5: 410–423 (2000).
Nicholson JK, Buckingham MJ, Sadler PJ. High-resolution proton NMR studies of vertebrate blood and plasma. Biochem 7 211: 605–615 (1983).
Nicholson JK, Wilson ID. High-resolution proton NMR spectroscopy of biological fluids. Prog NMR Spectr 21: 449–501 (1989).
Nicholson JK, Foxall PJD. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 67: 793–811(1995).
Petricoin EF III, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 395: 572–577 (2002).
Phipps AN, Stewart J, Wright B, Wilson ID. Effect of diet on the urinary excretion of hippuric acid and other dietary-derived aromatics in the rat. A complex interaction between diet, gut microflora and substrate specificity. Xenobiotica 28: 527–537 (1998).
Robertson DG, Reily MD, Sigler RE et al. Metabonomics: evaluation of nuclear nagnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci 57: 326–337 (2000).
Stevens GJ, Chambers J, Evering W, Deese A. Evaluation of metabonomics technology for liver and kidney toxicants in mice. 41st Meeting of the Society of Toxicology, Nashville (2002).
’t Hart BA, Vogels JTWE, Spijksma G et al. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci submitted (2002).
Wang S, Regnier FE. Proteomics based on selecting and quantifying cysteine containing peptides by covalent chromatography. J Chromatogr 924: 345–357 (2001).
Wang Y, Fejzo J, Heiser A et al. Application of metabonomics in drug design: can metabonomics and pharmacokinetics (PK) studies be conducted simultaneously in the same set of rats? 41st Meeting of the Society of Toxicology, Nashville (2002).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Breau, A.P., Cantor, G.H. (2003). Application of Metabonomics in the Pharmaceutical Industry. In: Harrigan, G.G., Goodacre, R. (eds) Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0333-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0333-0_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5025-5
Online ISBN: 978-1-4615-0333-0
eBook Packages: Springer Book Archive